{"hands_on_practices": [{"introduction": "A key step in diagnosing preeclampsia is quantifying proteinuria. While a 24-hour urine collection was once the standard, the spot urine protein-to-creatinine ratio offers a faster, more convenient alternative. This first exercise focuses on the fundamental skill of calculating this ratio from raw laboratory values and applying the diagnostic threshold, a critical first step in the evaluation of hypertensive disorders of pregnancy. [@problem_id:4465834]", "problem": "A pregnant individual at 34 weeks and 2 days with a history of chronic hypertension presents with sustained blood pressures in the range of $140-150 \\text{ mm Hg}$ systolic and $90-95 \\text{ mm Hg}$ diastolic over 4 hours, without headache, visual disturbance, right upper quadrant pain, or dyspnea. Physical examination is otherwise unremarkable. Laboratory testing reveals a platelet count of $210{,}000/\\mu\\text{L}$, serum creatinine of $0.7 \\text{ mg/dL}$, alanine aminotransferase of $22 \\text{ U/L}$, and aspartate aminotransferase of $24 \\text{ U/L}$. A spot urine (random clean-catch) is obtained, showing urine protein concentration of $45 \\text{ mg/dL}$ and urine creatinine concentration of $120 \\text{ mg/dL}$.\n\nStarting from foundational definitions used in obstetric practice, the diagnosis of preeclampsia without severe features requires new-onset hypertension after 20 weeks of gestation plus evidence of proteinuria, where proteinuria is defined by either a 24-hour urine protein of at least $300 \\text{ mg}$ or a protein-to-creatinine ratio in a random urine sample of at least $0.3$. The protein-to-creatinine ratio is the dimensionless quotient obtained by dividing urine protein concentration by urine creatinine concentration measured in the same sample.\n\nUsing these base definitions, compute the protein-to-creatinine ratio from the provided urine concentrations and determine whether the computed value meets the $\\ge 0.3$ threshold for proteinuria consistent with preeclampsia without severe features. Express your final computed ratio as a unitless number and round your answer to three significant figures.", "solution": "The task is to compute the protein-to-creatinine ratio from a spot urine sample, then compare the result to the diagnostic threshold for proteinuria used in the evaluation of preeclampsia without severe features.\n\nFoundational definitions and facts:\n- Preeclampsia is defined by new-onset hypertension after 20 weeks of gestation plus either proteinuria or specific end-organ dysfunction. In the absence of severe features, proteinuria can be established by either a 24-hour urine protein of at least $300 \\text{ mg}$ or a spot urine protein-to-creatinine ratio of at least $0.3$.\n- The protein-to-creatinine ratio in a random urine sample is the dimensionless quotient given by dividing the urine protein concentration by the urine creatinine concentration measured in the same sample. Because both concentrations are measured in the same units (for example, $\\text{mg/dL}$), the units cancel, yielding a unitless ratio that approximates grams of protein per gram of creatinine over a 24-hour period.\n\nLet the urine protein concentration be $P$ and the urine creatinine concentration be $C$. Given $P = 45 \\text{ mg/dL}$ and $C = 120 \\text{ mg/dL}$, the protein-to-creatinine ratio $R$ is:\n$$\nR = \\frac{P}{C} = \\frac{45}{120}.\n$$\nCompute the fraction:\n$$\n\\frac{45}{120} = \\frac{9}{24} = \\frac{3}{8} = 0.375.\n$$\nThis ratio is unitless because the $\\text{mg/dL}$ units cancel in the quotient.\n\nRounding to three significant figures:\n- The value $0.375$ already has three significant figures, so the rounded value remains $0.375$.\n\nComparison to the threshold for proteinuria:\n- The diagnostic threshold is $R \\ge 0.3$.\n- Since $0.375 \\ge 0.3$, the threshold for proteinuria is met, satisfying the proteinuria criterion for preeclampsia without severe features when combined with the described blood pressure findings, assuming no severe features are present.\n\nThe problem requests the final computed ratio as a unitless number rounded to three significant figures, which is $0.375$.", "answer": "$$\\boxed{0.375}$$", "id": "4465834"}, {"introduction": "The distinction between preeclampsia with and without severe features is paramount, as it dictates management and timing of delivery. This next practice challenges you to interpret evolving laboratory data, correctly identify a severe feature even in the absence of overt symptoms, and apply evidence-based guidelines to make a critical decision about patient care. This scenario [@problem_id:4465857] highlights how vigilant monitoring and correct interpretation of laboratory findings directly impact maternal and fetal outcomes.", "problem": "A $29$-year-old primigravid woman at 35 weeks 2 days with a history of gestational hypertension presents for routine follow-up. She has had home Blood Pressure (BP) readings in the $140-150/90-96 \\text{ mm Hg}$ range over the past week. In clinic today, BP is $148/94 \\text{ mm Hg}$. She denies headache, visual changes, and Right Upper Quadrant (RUQ) or epigastric pain. Fetal movement is normal. Physical examination is unremarkable with no edema, clonus, or focal neurologic findings. Laboratory results are notable for platelet count $165 \\times 10^3/\\mu\\text{L}$, serum creatinine $0.8 \\text{ mg/dL}$, urine protein-to-creatinine ratio $0.4$, aspartate aminotransferase (AST) $78 \\text{ U/L}$ (laboratory upper limit of normal $35 \\text{ U/L}$), and alanine aminotransferase (ALT) $92 \\text{ U/L}$ (laboratory upper limit of normal $40 \\text{ U/L}$). These transaminases were previously normal two weeks ago and have risen progressively.\n\nUsing foundational criteria for diagnosing preeclampsia and its severe features established by well-validated consensus guidelines (for example, those of the American College of Obstetricians and Gynecologists (ACOG) and Society for Maternal-Fetal Medicine (SMFM)), determine whether the current findings constitute a severe feature. Then, based on maternal-fetal risk principles, indicate the appropriate change in management at this gestational age.\n\nWhich one of the following is the best next step?\n\nA. This does not constitute a severe feature; continue outpatient expectant management and plan delivery at $37$ weeks without magnesium sulfate.\n\nB. This constitutes a severe feature (impaired liver function); admit for maternal-fetal monitoring, initiate magnesium sulfate for seizure prophylaxis, and proceed to delivery given gestational age $\\ge 34$ weeks after stabilization.\n\nC. This constitutes a severe feature only if accompanied by persistent RUQ pain; absent pain, maintain current management and plan elective delivery at $39$ weeks.\n\nD. This constitutes a severe feature; start antihypertensive therapy immediately and delay delivery until $37$ weeks without magnesium sulfate, as BP is not in the severe range.\n\nE. This does not constitute a severe feature; the likely diagnosis is intrahepatic cholestasis of pregnancy, so order serum bile acids and defer any change in management pending results.", "solution": "The validity of the problem statement is first assessed.\n\n**Step 1: Extract Givens**\n-   Patient: A $29$-year-old primigravid woman.\n-   Gestational Age (GA): 35 weeks 2 days.\n-   History: Gestational hypertension.\n-   Home Blood Pressure (BP): $140-150/90-96 \\text{ mm Hg}$ range over the past week.\n-   Clinic BP: $148/94 \\text{ mm Hg}$.\n-   Symptoms: Denial of headache, visual changes, and Right Upper Quadrant (RUQ) or epigastric pain.\n-   Fetal Status: Normal fetal movement.\n-   Physical Examination: Unremarkable; no edema, clonus, or focal neurologic findings.\n-   Laboratory Data:\n    -   Platelet count: $165 \\times 10^3/\\mu\\text{L}$.\n    -   Serum creatinine: $0.8 \\text{ mg/dL}$.\n    -   Urine protein-to-creatinine ratio: $0.4$.\n    -   Aspartate aminotransferase (AST): $78 \\text{ U/L}$ (laboratory upper limit of normal $35 \\text{ U/L}$).\n    -   Alanine aminotransferase (ALT): $92 \\text{ U/L}$ (laboratory upper limit of normal $40 \\text{ U/L}$).\n-   Additional Context: Transaminases were previously normal two weeks ago and have shown progressive increase.\n\n**Step 2: Validate Using Extracted Givens**\n-   **Scientifically Grounded:** The problem describes a realistic clinical case within obstetrics, concerning hypertensive disorders of pregnancy. The data, terminology, and diagnostic framework are consistent with established medical science and clinical practice guidelines (e.g., ACOG). The scenario is biologically and medically plausible.\n-   **Well-Posed:** The problem provides sufficient, consistent data to arrive at a diagnosis and formulate a management plan based on standard-of-care guidelines. It asks for the \"best next step,\" which implies a single optimal course of action based on the provided information.\n-   **Objective:** The problem statement consists of objective clinical findings (BP measurements, lab results) and patient-reported symptoms (or lack thereof). It avoids subjective or ambiguous language.\n\n**Step 3: Verdict and Action**\nThe problem statement is valid. It is scientifically sound, well-posed, and objective. A solution will be derived based on a formal analysis of the clinical data against established diagnostic criteria.\n\n**Derivation of Solution**\n\nThe analysis proceeds in three stages:\n1.  Establish the diagnosis of preeclampsia.\n2.  Assess for the presence of severe features.\n3.  Determine the appropriate management based on the diagnosis, severity, and gestational age.\n\n**1. Diagnosis of Preeclampsia**\nAccording to consensus guidelines (e.g., ACOG), the diagnosis of preeclampsia is established by new-onset hypertension after $20$ weeks of gestation accompanied by either proteinuria or specific signs of end-organ dysfunction.\n-   **Hypertension:** The patient has a history of gestational hypertension. Multiple BP readings are in the hypertensive range ($\\ge 140 \\text{ mm Hg}$ systolic or $\\ge 90 \\text{ mm Hg}$ diastolic). Her clinic BP is $148/94 \\text{ mm Hg}$. This criterion is met.\n-   **Proteinuria:** This is defined as a urine protein-to-creatinine ratio of $\\ge 0.3$, a $24$-hour urine protein of $\\ge 300 \\text{ mg}$, or a dipstick reading of $\\ge 2+$. The patient's urine protein-to-creatinine ratio is $0.4$, which is greater than the threshold of $0.3$. This criterion is met.\n\nTherefore, the patient fulfills the diagnostic criteria for preeclampsia.\n\n**2. Assessment for Severe Features**\nPreeclampsia is further classified as \"with severe features\" if any of the following are present:\n-   **Severe hypertension:** Systolic BP $\\ge 160 \\text{ mm Hg}$ or diastolic BP $\\ge 110 \\text{ mm Hg}$. The patient's BP of $148/94 \\text{ mm Hg}$ does not meet this criterion.\n-   **Thrombocytopenia:** Platelet count $ 100 \\times 10^3/\\mu\\text{L}$. The patient's platelet count is $165 \\times 10^3/\\mu\\text{L}$, which is normal. This criterion is not met.\n-   **Impaired liver function:** This is defined as serum transaminase concentrations (AST or ALT) elevated to at least twice ($2\\times$) the upper limit of normal OR severe persistent RUQ or epigastric pain unresponsive to medication.\n    -   The patient's AST is $78$ U/L. The upper limit of normal (ULN) is $35$ U/L. $2 \\times 35 \\text{ U/L} = 70 \\text{ U/L}$. The patient's AST ($78 \\text{ U/L}$) is greater than twice the ULN.\n    -   The patient's ALT is $92$ U/L. The ULN is $40$ U/L. $2 \\times 40 \\text{ U/L} = 80 \\text{ U/L}$. The patient's ALT ($92 \\text{ U/L}$) is also greater than twice the ULN.\n    -   Thus, the criterion for impaired liver function is met based on the liver enzyme levels, irrespective of the absence of RUQ/epigastric pain.\n-   **Progressive renal insufficiency:** Serum creatinine $> 1.1 \\text{ mg/dL}$ or a doubling of baseline creatinine. The patient's creatinine is $0.8 \\text{ mg/dL}$. This criterion is not met.\n-   **Pulmonary edema:** Not present on examination.\n-   **New-onset cerebral or visual disturbances:** The patient denies these symptoms.\n\nConclusion: The patient has preeclampsia with a severe feature, specifically impaired liver function.\n\n**3. Determination of Management**\nThe management of preeclampsia with severe features depends critically on the gestational age.\n-   The patient is at 35 weeks 2 days gestation.\n-   For preeclampsia with severe features diagnosed at or beyond $34$ weeks $0$ days of gestation, standard-of-care guidelines recommend delivery after maternal stabilization. Expectant management is not recommended due to high maternal and fetal risks.\n-   Maternal stabilization for preeclampsia with severe features includes seizure prophylaxis with intravenous magnesium sulfate. This is administered to prevent eclampsia, a life-threatening complication.\n-   Therefore, the correct course of action is to admit the patient to the hospital for maternal and fetal monitoring, initiate magnesium sulfate for seizure prophylaxis, and proceed with delivery.\n\n**Evaluation of Options**\n\n**A. This does not constitute a severe feature; continue outpatient expectant management and plan delivery at $37$ weeks without magnesium sulfate.**\nThis statement is incorrect. The patient's liver transaminase levels (AST $> 2\\times$ ULN and ALT $> 2\\times$ ULN) definitively constitute a severe feature. Consequently, expectant management until $37$ weeks is not appropriate. Delivery is indicated, and magnesium sulfate is required for seizure prophylaxis.\nVerdict: **Incorrect**.\n\n**B. This constitutes a severe feature (impaired liver function); admit for maternal-fetal monitoring, initiate magnesium sulfate for seizure prophylaxis, and proceed to delivery given gestational age $\\ge 34$ weeks after stabilization.**\nThis statement correctly identifies that the findings constitute a severe feature (impaired liver function). The proposed management plan—admission, maternal-fetal monitoring, magnesium sulfate for seizure prophylaxis, and proceeding to delivery—is fully consistent with established guidelines for managing preeclampsia with severe features at a gestational age of 35 weeks 2 days.\nVerdict: **Correct**.\n\n**C. This constitutes a severe feature only if accompanied by persistent RUQ pain; absent pain, maintain current management and plan elective delivery at $39$ weeks.**\nThis statement is incorrect. The diagnostic criteria for impaired liver function as a severe feature are disjunctive: elevated transaminases OR severe pain. The presence of transaminases more than twice the ULN is sufficient on its own. Since a severe feature is present, planning for delivery at $39$ weeks is inappropriate and dangerous.\nVerdict: **Incorrect**.\n\n**D. This constitutes a severe feature; start antihypertensive therapy immediately and delay delivery until $37$ weeks without magnesium sulfate, as BP is not in the severe range.**\nThis statement is incorrect on multiple grounds. While it correctly identifies the presence of a severe feature, the proposed management is flawed. First, delaying delivery until $37$ weeks is contraindicated for preeclampsia with severe features at this gestational age. Second, magnesium sulfate is indicated for seizure prophylaxis in all cases of preeclampsia with severe features, not just those with severe-range BPs. Third, immediate antihypertensive therapy is reserved for severe-range BPs ($\\ge 160/110 \\text{ mm Hg}$), which this patient does not have.\nVerdict: **Incorrect**.\n\n**E. This does not constitute a severe feature; the likely diagnosis is intrahepatic cholestasis of pregnancy, so order serum bile acids and defer any change in management pending results.**\nThis statement is incorrect. The findings do constitute a severe feature of preeclampsia. While intrahepatic cholestasis of pregnancy (ICP) can cause elevated transaminases, the patient's clinical picture of hypertension and proteinuria makes preeclampsia the primary and most urgent diagnosis. Attributing the findings to ICP and delaying definitive management for preeclampsia would be a critical clinical error, placing both mother and fetus at significant risk.\nVerdict: **Incorrect**.", "answer": "$$\\boxed{B}$$", "id": "4465857"}, {"introduction": "Managing gestational hypertension often involves initiating and titrating antihypertensive medication to achieve target blood pressures, mitigating maternal risk while supporting the pregnancy. This final exercise simulates this process through a hypothetical dose-response model, providing a hands-on opportunity to practice the quantitative reasoning required for systematic medication adjustment. While the model simplifies complex pharmacology, it provides a structured framework for thinking through titration protocols to achieve a therapeutic goal. [@problem_id:4465881]", "problem": "A pregnant patient at gestational age 28 weeks is diagnosed with gestational hypertension, defined as persistently elevated Blood Pressure (BP) without proteinuria or severe features after 20 weeks of gestation. Her baseline clinic measurements on two occasions are Systolic Blood Pressure (SBP) $152 \\text{ mm Hg}$ and Diastolic Blood Pressure (DBP) $94 \\text{ mm Hg}$. She has no signs or symptoms of severe features. You initiate oral labetalol at $100 \\text{ mg}$ twice daily, where twice daily (BID) means two doses per day. The clinical protocol is to titrate by increasing each dose by $100 \\text{ mg}$ (that is, add $100 \\text{ mg}$ to the morning dose and $100 \\text{ mg}$ to the evening dose) every 3 days if the BP goal is not reached, with a maximum typical daily dose of $2400 \\text{ mg}$. The BP goal is $SBP  140 \\text{ mm Hg}$ and $DBP  90 \\text{ mm Hg}$, both strictly below their respective thresholds.\n\nAssume the following foundational pharmacodynamic model grounded in small-increment dose-response and steady-state attainment within each titration interval:\n- Each increment of $100 \\text{ mg}$ per dose (that is, an increase of $200 \\text{ mg}$ per day) produces an additional steady-state reduction of SBP by $4 \\text{ mm Hg}$ and of DBP by $2.5 \\text{ mm Hg}$ relative to the immediately prior dose level.\n- The effect is approximately linear in this small-increment range and does not exceed physiologic ceilings of $30 \\text{ mm Hg}$ systolic and $20 \\text{ mm Hg}$ diastolic reduction; assume doses used here remain within the linear regime.\n- Within each 3-day interval, steady state at the new dose is achieved, and BP is assessed at the end of the interval to decide on further titration.\n- The per-dose amount at the $n$-th step (counting the initial $100 \\text{ mg}$ BID as step $n=1$) is $100 + (n-1) \\times 100 \\text{ mg}$, administered BID. The corresponding total daily dose is twice the per-dose amount and cannot exceed $2400 \\text{ mg}$.\n\nStarting at day $0$ on $100 \\text{ mg}$ BID, following the above titration and evaluation schedule, and assuming perfect adherence, no adverse effects mandating changes, and that the only driver of BP change is the dose increment model stated, determine the total time in days required to achieve the BP goal $SBP  140 \\text{ mm Hg}$ and $DBP  90 \\text{ mm Hg}$. Express your final answer as the total number of days. No rounding is required.", "solution": "The problem is deemed valid as it is scientifically grounded, well-posed, and objective. It provides a clear, self-contained, and consistent set of conditions to model a clinical scenario using deterministic rules.\n\nThe problem asks for the total time in days to achieve a specific blood pressure goal by titrating a medication, labetalol, according to a defined protocol. We can solve this by modeling the patient's blood pressure over time as a function of the medication dosage.\n\nFirst, we establish the initial conditions and the therapeutic goal.\nThe baseline blood pressure (BP) measurements are:\nSystolic Blood Pressure, $SBP_0 = 152 \\text{ mm Hg}$.\nDiastolic Blood Pressure, $DBP_0 = 94 \\text{ mm Hg}$.\n\nThe therapeutic goal is to bring the BP to values strictly below the thresholds:\n$SBP_{goal}  140 \\text{ mm Hg}$.\n$DBP_{goal}  90 \\text{ mm Hg}$.\nBoth conditions must be met concurrently.\n\nThe treatment starts on day $0$ and involves a series of titration steps. Let $n$ represent the step number, starting with $n=1$ for the initial dose. Each step lasts for an interval of $T=3$ days, with the BP being evaluated at the end of each interval. Thus, the evaluation for step $n$ occurs at a total time of $t_n = n \\times T$ days.\n\nThe medication is administered twice daily (BID). The dose titration protocol specifies that for each new step, the amount per dose is increased by $100$ mg. The problem provides a formula for the per-dose amount at step $n$:\n$D_{dose, n} = 100 + (n-1) \\times 100 = n \\times 100$ mg.\n\nThe pharmacodynamic model states that each increment of $100$ mg per dose causes an additional reduction in BP. Since the per-dose amount at step $n$ is $n \\times 100$ mg, it represents $n$ such increments relative to a zero-dose baseline. The effects are cumulative.\nThe reduction per increment is given as:\n$\\Delta SBP_{inc} = 4 \\text{ mm Hg}$ for systolic pressure.\n$\\Delta DBP_{inc} = 2.5 \\text{ mm Hg}$ for diastolic pressure.\n\nThe total reduction in BP at the end of step $n$ is proportional to the number of increments, $n$.\nTotal SBP reduction at step $n$: $\\Delta SBP_n = n \\times \\Delta SBP_{inc} = 4n \\text{ mm Hg}$.\nTotal DBP reduction at step $n$: $\\Delta DBP_n = n \\times \\Delta DBP_{inc} = 2.5n \\text{ mm Hg}$.\n\nUsing these relationships, we can express the SBP and DBP at the evaluation time $t_n$ for step $n$ as:\n$SBP_n = SBP_0 - \\Delta SBP_n = 152 - 4n$\n$DBP_n = DBP_0 - \\Delta DBP_n = 94 - 2.5n$\n\nWe need to find the smallest integer $n \\ge 1$ for which both BP goals are met. We can set up two inequalities:\n\n1. For Systolic Blood Pressure:\n$SBP_n  140$\n$152 - 4n  140$\nRearranging the inequality to solve for $n$:\n$152 - 140  4n$\n$12  4n$\n$n > \\frac{12}{4}$\n$n > 3$\nSince $n$ must be an integer, the smallest integer value of $n$ that satisfies the SBP goal is $n_{SBP} = 4$.\n\n2. For Diastolic Blood Pressure:\n$DBP_n  90$\n$94 - 2.5n  90$\nRearranging the inequality:\n$94 - 90  2.5n$\n$4  2.5n$\n$n > \\frac{4}{2.5}$\n$n > 1.6$\nSince $n$ must be an integer, the smallest integer value of $n$ that satisfies the DBP goal is $n_{DBP} = 2$.\n\nTo achieve the overall therapeutic goal, both conditions must be satisfied simultaneously. This requires an integer $n$ that is greater than $3$ AND greater than $1.6$. The more restrictive condition is $n > 3$. Therefore, the minimum integer step number $n_{req}$ that satisfies both inequalities is the maximum of the individual minimums:\n$n_{req} = \\max(n_{SBP}, n_{DBP}) = \\max(4, 2) = 4$.\n\nThe goal is achieved at the evaluation of the $4$-th step. The total time elapsed to reach this point is:\n$t_{final} = n_{req} \\times T = 4 \\times 3 = 12$ days.\n\nLet's verify the BP at $n=4$:\n$SBP_4 = 152 - 4(4) = 152 - 16 = 136 \\text{ mm Hg}$.\n$DBP_4 = 94 - 2.5(4) = 94 - 10 = 84 \\text{ mm Hg}$.\nIndeed, $136  140$ and $84  90$, so the goal is met at this time.\nAt $n=3$, the SBP would be $152 - 4(3) = 140$, which is not strictly less than $140$, so the goal would not have been met at day $9$.\n\nFinally, we check if the dose at step $n=4$ is within the allowed maximum.\nThe per-dose amount is $D_{dose, 4} = 4 \\times 100 = 400$ mg.\nThe total daily dose is $2 \\times D_{dose, 4} = 2 \\times 400 = 800$ mg.\nThis is less than the maximum typical daily dose of $2400$ mg, so the solution is valid within the problem's constraints.\n\nThe total time required to achieve the BP goal is $12$ days.", "answer": "$$\n\\boxed{12}\n$$", "id": "4465881"}]}